DK3390448T3 - Intravesikal terapi af blærekræft - Google Patents

Intravesikal terapi af blærekræft Download PDF

Info

Publication number
DK3390448T3
DK3390448T3 DK16819062.7T DK16819062T DK3390448T3 DK 3390448 T3 DK3390448 T3 DK 3390448T3 DK 16819062 T DK16819062 T DK 16819062T DK 3390448 T3 DK3390448 T3 DK 3390448T3
Authority
DK
Denmark
Prior art keywords
bladder cancer
intravesical therapy
intravesical
therapy
bladder
Prior art date
Application number
DK16819062.7T
Other languages
English (en)
Inventor
Kjetil Hestdal
Original Assignee
Photocure Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure Asa filed Critical Photocure Asa
Application granted granted Critical
Publication of DK3390448T3 publication Critical patent/DK3390448T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
DK16819062.7T 2015-12-17 2016-12-19 Intravesikal terapi af blærekræft DK3390448T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522311.8A GB201522311D0 (en) 2015-12-17 2015-12-17 Use
PCT/EP2016/081798 WO2017103280A1 (en) 2015-12-17 2016-12-19 Intravesical therapy for bladder cancer

Publications (1)

Publication Number Publication Date
DK3390448T3 true DK3390448T3 (da) 2024-07-22

Family

ID=55311161

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16819062.7T DK3390448T3 (da) 2015-12-17 2016-12-19 Intravesikal terapi af blærekræft

Country Status (12)

Country Link
US (2) US20180371101A1 (da)
EP (1) EP3390448B1 (da)
JP (1) JP2018538308A (da)
KR (1) KR102878726B1 (da)
CN (1) CN108699147B (da)
AU (1) AU2016372570B2 (da)
DK (1) DK3390448T3 (da)
ES (1) ES2981986T3 (da)
FI (1) FI3390448T3 (da)
GB (1) GB201522311D0 (da)
PL (1) PL3390448T3 (da)
WO (1) WO2017103280A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
JP7106538B2 (ja) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド 抗体およびその使用方法
US11266619B2 (en) * 2017-12-01 2022-03-08 Sbi Pharmaceuticals Co., Ltd. Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor
CN120957714A (zh) 2023-03-07 2025-11-14 光治疗Asa公司 膀胱癌疗法
WO2026052815A1 (en) 2024-09-05 2026-03-12 Photocure Asa Use of hal in a method for predicting bladder cancer immunotherapy response

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE202076T1 (de) 1995-03-10 2001-06-15 Photocure Asa Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
KR101814408B1 (ko) * 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
WO2013181452A1 (en) 2012-05-31 2013-12-05 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
JP6954648B2 (ja) * 2015-10-19 2021-10-27 シージー オンコロジー， インコーポレイテッド 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use

Also Published As

Publication number Publication date
KR102878726B1 (ko) 2025-10-29
CA3008548A1 (en) 2017-06-22
JP2018538308A (ja) 2018-12-27
RU2018124866A (ru) 2020-01-17
US11066478B2 (en) 2021-07-20
PL3390448T3 (pl) 2024-09-16
KR20180094988A (ko) 2018-08-24
FI3390448T3 (fi) 2024-07-10
GB201522311D0 (en) 2016-02-03
ES2981986T3 (es) 2024-10-14
WO2017103280A9 (en) 2017-11-09
CN108699147A (zh) 2018-10-23
EP3390448B1 (en) 2024-06-05
CN108699147B (zh) 2022-11-01
AU2016372570A1 (en) 2018-07-12
AU2016372570B2 (en) 2024-01-18
US20180371101A1 (en) 2018-12-27
RU2018124866A3 (da) 2020-02-26
BR112018012116A2 (en) 2018-12-04
US20190241672A1 (en) 2019-08-08
WO2017103280A1 (en) 2017-06-22
EP3390448A1 (en) 2018-10-24

Similar Documents

Publication Publication Date Title
IL255261A0 (en) Methods for treating cancer
PL3283527T3 (pl) Leczenie skojarzone nowotworów
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
IL263802A (en) Cancer treatment combinations
DK3851537T5 (da) Behandling af hyperbilirubinæmi
HUE059694T2 (hu) Készítmény rák kezelésére
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
DK3262066T4 (da) Genterapi
IL258521B1 (en) Combination therapy for the treatment of cancer
PL3197456T3 (pl) Leczenie nowotworów
DK3622953T3 (da) Kombinationsbehandling af cancer
EP3413927A4 (en) CANCER THERAPY
LT3576740T (lt) Vėžio gydymas
DK3307267T3 (da) Behandling af multipel sklerose
PT3134119T (pt) Tratamento do cancro
DK3390448T3 (da) Intravesikal terapi af blærekræft
DK3393478T3 (da) Kombinationsterapi
EP3362091A4 (en) COMBINATION THERAPY
DK3532076T3 (da) Immunterapeutiske behandlinger af tumorer
IL254825A0 (en) Methods of treatment with taselisib
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
IL246558A0 (en) Novel methods for treating cancer
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
LT3324951T (lt) Peritoninis terapinis skystis
DK3407909T5 (da) Cancerbehandling